title: Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation.
abstract: Polyclonal intravenous immunoglobulin (IVIg) treatment reduces crossmatch positivity and increases rates of transplantation in highly sensitised patients (HS). We quantified the panel reactive antibody (PRA) by microlymphocytotoxicity (MLCC), and we analysed anti-HLA class I and class II IgG specific antibody repertoire by Luminex before and after IVIg infusion alone in HS patients awaiting kidney transplantation. Five patients received three monthly infusions of 1 g/kg of IVIg. Serum samples collected pre and post IVIg treatment were submitted for PRA analysis by MLCC. Anti-class I and anti-class II antibody specificities were then tested by Luminex. We focused on the anti-HLA class I and class II antibodies directed against HLA expressed by a previous graft. We also analysed the anti-HLA antibody repertoire in three patients who had not received IVIg infusion. The PRA level determined by MLCC decreased significantly in one of the five patients, dropping from 40% to 17%. The Luminex assay showed fluctuations of the anti-HLA antibody levels over time, but no significant longterm modifications of the anti-HLA antibody repertoire were observed, even in the patient with a strong and prolonged reduction of the PRA determined by MLCC. Our results show that IVIg at 1 g/kg is not sufficient to reduce PRA and does not modify the repertoire of specific anti-HLA antibody determined by Luminex.
authors.affiliation: Immunology and Transplant Unit, Geneva University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva, Switzerland.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Ferrari-Lacraz
authors.forename: Vincent
authors.initials: V
authors.lastname: Aubert
authors.forename: Leo
authors.initials: L
authors.lastname: Buhler
authors.forename: Manuel
authors.initials: M
authors.lastname: Pascual
authors.forename: Irmgard
authors.initials: I
authors.lastname: Andresen
authors.forename: Isabelle
authors.initials: I
authors.lastname: Binet
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Martin
authors.forename: Jean
authors.initials: J
authors.lastname: Villard
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D019172:Transplantation Conditioning / Q000379:methods*
chemical_list: D000906:Antibodies; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous